PCIDB

KNApSAcK Metabolite C00001783

Metabolite

KNApSAcK Entry

id C00001783
Name Vincristine
CAS RN 57-22-7
Standard InChI InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
Standard InChI (Main Layer) InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3

Cluster

Phytochemical cluster No. 4
KCF-S cluster No. 2360

Link

ChEMBL

By standard InChI CHEMBL90555
By standard InChI Main Layer CHEMBL90555 CHEMBL1363013 CHEMBL1396825 CHEMBL1740907 CHEMBL2134016

KEGG

By LinkDB C07204

CTD

By CAS RN D014750

Human Protein / Gene in interaction

129 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL90555 CHEMBL1363013 CHEMBL1614110 (1) CHEMBL1741321 (1)
CHEMBL1909136 (2)
1 / 0
P42345 Serine/threonine-protein kinase mTOR Enzyme CHEMBL1396825 CHEMBL1613805 (1)
0 / 0
P33527 Multidrug resistance-associated protein 1 drugs CHEMBL90555 CHEMBL2077586 (1) CHEMBL2075733 (1)
CHEMBL2075740 (1) CHEMBL2078574 (1)
0 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL1363013 CHEMBL1613992 (1) CHEMBL1613995 (1)
7 / 44
Q9Y6L6 Solute carrier organic anion transporter family member 1B1 Electrochemical transporter CHEMBL90555 CHEMBL2169429 (1) CHEMBL2169432 (2)
1 / 0
O94956 Solute carrier organic anion transporter family member 2B1 Unclassified protein CHEMBL90555 CHEMBL2169431 (1)
0 / 0
Q99700 Ataxin-2 Unclassified protein CHEMBL1396825 CHEMBL2114784 (1)
1 / 1
P49798 Regulator of G-protein signaling 4 Unclassified protein CHEMBL1396825 CHEMBL1794499 (1)
2 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL90555 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL90555 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL90555 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL90555 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL90555 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL90555 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL90555 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL90555 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL90555 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL90555 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL90555 CHEMBL1909197 (2)
2 / 2
P02545 Prelamin-A/C Unclassified protein CHEMBL90555 CHEMBL1614544 (1)
11 / 10
P00918 Carbonic anhydrase 2 Lyase CHEMBL90555 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL90555 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL90555 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL90555 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL90555 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL90555 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909093 (2)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL90555 CHEMBL1908285 (1) CHEMBL1908286 (1)
CHEMBL1908289 (1) CHEMBL1908291 (1)
CHEMBL1908292 (1) CHEMBL2076285 (1)
CHEMBL2076286 (1) CHEMBL2075689 (1)
CHEMBL2076208 (1) CHEMBL2076219 (1)
CHEMBL2076066 (1) CHEMBL2078149 (2)
CHEMBL2078578 (1) CHEMBL2078581 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL90555 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL90555 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL90555 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL90555 CHEMBL1363013 CHEMBL1741325 (1) CHEMBL1909135 (2)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL90555 CHEMBL1909203 (2)
1 / 11
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL90555 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL90555 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL90555 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL90555 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL90555 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL90555 CHEMBL1909214 (2)
0 / 0
P11926 Ornithine decarboxylase Lyase CHEMBL90555 CHEMBL1008926 (1)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL90555 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL90555 CHEMBL1909096 (2)
1 / 1
O15296 Arachidonate 15-lipoxygenase B Enzyme CHEMBL1363013 CHEMBL1613800 (1)
0 / 0
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL90555 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL90555 CHEMBL1909166 (2)
1 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL90555 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL1363013 CHEMBL1614456 (1) CHEMBL1613803 (1)
0 / 0
P42858 Huntingtin Unclassified protein CHEMBL90555 CHEMBL1613918 (1)
1 / 1
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL90555 CHEMBL1794584 (1)
2 / 0
O75496 Geminin Unclassified protein CHEMBL90555 CHEMBL2114780 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL90555 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL90555 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL90555 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL90555 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL90555 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL90555 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL90555 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL90555 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL90555 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL90555 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL90555 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL90555 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL90555 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL90555 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL90555 CHEMBL1909119 (2)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL1396825 CHEMBL1738610 (1)
0 / 0
Q9NPD5 Solute carrier organic anion transporter family member 1B3 Electrochemical transporter CHEMBL90555 CHEMBL2169430 (1) CHEMBL2169433 (2)
1 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL90555 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL90555 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL90555 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL90555 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL90555 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL90555 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL90555 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL90555 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL90555 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL90555 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL90555 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL90555 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL90555 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL90555 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL90555 CHEMBL1363013 CHEMBL1741322 (1) CHEMBL1909132 (2)
0 / 0
Q92887 Canalicular multispecific organic anion transporter 1 Unclassified protein CHEMBL90555 CHEMBL1006005 (1) CHEMBL2077557 (1)
CHEMBL2077634 (1) CHEMBL2078561 (1)
1 / 1
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL1396825 CHEMBL1737868 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL90555 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL90555 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL90555 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL90555 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL90555 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL90555 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL90555 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL90555 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL90555 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL90555 CHEMBL1909168 (2)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL1363013 CHEMBL1614240 (1)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL90555 CHEMBL1363013 CHEMBL1741323 (1) CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL90555 CHEMBL1363013 CHEMBL1614108 (1) CHEMBL1613886 (1)
CHEMBL1741324 (1) CHEMBL1743273 (1)
CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL90555 CHEMBL1909137 (2)
0 / 0
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL1396825 CHEMBL1737980 (1)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL90555 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL90555 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL90555 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL90555 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL90555 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL90555 CHEMBL1909128 (2)
0 / 0
P40225 Thrombopoietin Unclassified protein CHEMBL1363013 CHEMBL1614086 (1) CHEMBL1614034 (1)
1 / 1
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL90555 CHEMBL1396825 CHEMBL1738442 (2)
0 / 0
Q96QA9 Multidrug resistance associated protein Unclassified protein CHEMBL90555 CHEMBL2076177 (1)
0 / 0
Q5T3U5 Multidrug resistance-associated protein 7 Unclassified protein CHEMBL90555 CHEMBL2076524 (1)
0 / 0
Q13748 Tubulin alpha-3C/D chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
P68366 Tubulin alpha-4A chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q9H4B7 Tubulin beta-1 chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
1 / 0
P04350 Tubulin beta-4A chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
2 / 0
Q3ZCM7 Tubulin beta-8 chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
P07437 Tubulin beta chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q71U36 Tubulin alpha-1A chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
1 / 1
P68371 Tubulin beta-4B chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q13509 Tubulin beta-3 chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
2 / 1
P68363 Tubulin alpha-1B chain Unclassified protein CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q13885 Tubulin beta-2A chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q6PEY2 Tubulin alpha-3E chain Unclassified protein CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q9BQE3 Tubulin alpha-1C chain Unclassified protein CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q9BUF5 Tubulin beta-6 chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
0 / 0
Q9BVA1 Tubulin beta-2B chain Structural CHEMBL90555 CHEMBL815200 (1) CHEMBL867647 (1)
1 / 0

CTD interaction (296)

compound gene gene name gene description interaction interaction type form reference
pmid
D014750 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA1 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 26154 ABCA12
ARCI4A
ARCI4B
ICR2B
LI2
ATP-binding cassette, sub-family A (ABC1), member 12 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA12 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 24 ABCA4
ABC10
ABCR
ARMD2
CORD3
FFM
RMP
RP19
STGD
STGD1
ATP-binding cassette, sub-family A (ABC1), member 4 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA4 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 23461 ABCA5
ABC13
EST90625
ATP-binding cassette, sub-family A (ABC1), member 5 [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA5 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 10351 ABCA8
ATP-binding cassette, sub-family A (ABC1), member 8 [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA8 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the susceptibility to Vincristine affects response to substance
protein 15645438
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the uptake of Vincristine affects uptake
protein 11934808
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 7905786
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in decreased uptake of Vincristine decreases uptake
protein 10617675
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased transport of Vincristine increases transport
protein 16316932
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Cyclosporine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 7905786
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Estradiol results in decreased expression of ABCB1 protein] which results in increased uptake of and results in increased susceptibility to Vincristine decreases expression
/ increases response to substance
/ increases uptake
protein 16925584
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Fenofibrate inhibits the reaction [ABCB1 protein results in increased transport of Vincristine] decreases reaction
/ increases transport
protein 16316932
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Flupenthixol analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 7905786
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Vincristine affects cotreatment
/ decreases response to substance
protein 11792417
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) NR1I2 protein promotes the reaction [Vincristine results in increased expression of ABCB1 protein] increases expression
/ increases reaction
protein 20041327
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine decreases response to substance
/ increases expression
21833476
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB1 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Vincristine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA increases activity
/ increases expression
mRNA 20041327
D014750 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Vincristine results in increased expression of ABCB1 protein increases expression
protein 15239124
16038730
20041327
D014750 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 ABCB11 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5244 ABCB4
ABC21
GBD1
ICP3
MDR2
MDR2/3
MDR3
PFIC-3
PGY3
ATP-binding cassette, sub-family B (MDR/TAP), member 4 (EC:3.6.3.44) [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB4 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 10058 ABCB6
ABC
ABC14
DUH3
LAN
MCOPCB7
MTABC3
PRP
umat
ATP-binding cassette, sub-family B (MDR/TAP), member 6 [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB6 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine affects export
/ decreases response to substance
protein 15896345
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the export of Vincristine affects export
protein 15896345
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the susceptibility to Vincristine affects response to substance
protein 12731862
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein affects the transport of Vincristine affects transport
protein 10685512
15581632
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein mutant form affects the transport of Vincristine affects transport
protein 15581632
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 10900222
11278867
11778547
12067707
15044619
15180633
15896345
16042792
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15180633
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Doxorubicin inhibits the reaction [ABCC1 protein affects the transport of Vincristine] affects transport
/ decreases reaction
protein 10685512
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases response to substance
/ increases reaction
protein 10900222
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Vincristine affects expression
/ affects response to substance
mRNA 10348353
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 myricetin inhibits the reaction [ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine] affects export
/ decreases reaction
/ decreases response to substance
protein 15896345
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 myricetin inhibits the reaction [ABCC1 protein affects the export of Vincristine] affects export
/ decreases reaction
protein 15896345
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 myricetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15896345
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15180633
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Vincristine inhibits the reaction [ABCC1 protein affects the transport of fluorexon] affects transport
/ decreases reaction
protein 10685512
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Vincristine inhibits the reaction [Glutathione promotes the reaction [ABCC1 results in increased transport of methylarsine analog]] decreases reaction
/ increases reaction
/ increases transport
21918036
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC1 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15180633
D014750 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 19841739
D014750 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 ABCC10 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 19841739
D014750 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 imatinib inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 19841739
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine affects export
/ decreases response to substance
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein affects the export of Vincristine affects export
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 myricetin inhibits the reaction [ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine] affects export
/ decreases reaction
/ decreases response to substance
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 myricetin inhibits the reaction [ABCC2 protein affects the export of Vincristine] affects export
/ decreases reaction
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 myricetin inhibits the reaction [ABCC2 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15896345
D014750 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC2 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 8714 ABCC3
ABC31
EST90757
MLP2
MOAT-D
MRP3
cMOAT2
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC3 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 [Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC4 mRNA decreases expression
/ decreases response to substance
mRNA 19944135
D014750 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 ABCC5 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCC5 mRNA affects expression
/ decreases response to substance
mRNA 19944135
D014750 368 ABCC6
ABC34
ARA
EST349056
GACI2
MLP1
MOAT-E
MOATE
MRP6
PXE
PXE1
URG7
ATP-binding cassette, sub-family C (CFTR/MRP), member 6 [Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC6 mRNA decreases expression
/ decreases response to substance
mRNA 19944135
D014750 5825 ABCD3
ABC43
PMP70
PXMP1
ZWS2
ATP-binding cassette, sub-family D (ALD), member 3 [Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCD3 mRNA decreases expression
/ decreases response to substance
mRNA 19944135
D014750 9619 ABCG1
ABC8
WHITE1
ATP-binding cassette, sub-family G (WHITE), member 1 [Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG1 mRNA decreases expression
/ decreases response to substance
mRNA 19944135
D014750 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine decreases expression
/ decreases response to substance
21833476
D014750 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCG2 mRNA decreases response to substance
/ increases expression
mRNA 19944135
D014750 64137 ABCG4
WHITE2
ATP-binding cassette, sub-family G (WHITE), member 4 [Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG4 mRNA decreases expression
/ decreases response to substance
mRNA 19944135
D014750 81569 ACTL8
CT57
actin-like 8 ACTL8 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 154 ADRB2
ADRB2R
ADRBR
B2AR
BAR
BETA2AR
adrenoceptor beta 2, surface ADRB2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
21245421
D014750 57379 AICDA
AID
ARP2
CDA2
HIGM2
activation-induced cytidine deaminase (EC:3.5.4.38) AICDA gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Vincristine promotes the reaction [NVP ADW742 inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 16740780
D014750 216 ALDH1A1
ALDC
ALDH-E1
ALDH1
ALDH11
PUMB1
RALDH1
aldehyde dehydrogenase 1 family, member A1 (EC:1.2.1.36) ALDH1A1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 410 ARSA
MLD
arylsulfatase A (EC:3.1.6.8) ARSA gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 259266 ASPM
ASP
Calmbp1
MCPH5
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) Vincristine results in increased expression of ASPM mRNA increases expression
mRNA 17374387
D014750 538 ATP7A
DSMAX
MK
MNK
SMAX3
ATPase, Cu++ transporting, alpha polypeptide (EC:3.6.3.54) ATP7A protein results in decreased susceptibility to Vincristine decreases response to substance
protein 17510416
D014750 540 ATP7B
PWD
WC1
WD
WND
ATPase, Cu++ transporting, beta polypeptide (EC:3.6.3.54) ATP7B gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6790 AURKA
AIK
ARK1
AURA
AURORA2
BTAK
PPP1R47
STK15
STK6
STK7
aurora kinase A (EC:2.7.11.1) AURKA mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6790 AURKA
AIK
ARK1
AURA
AURORA2
BTAK
PPP1R47
STK15
STK6
STK7
aurora kinase A (EC:2.7.11.1) Vincristine results in increased expression of AURKA mRNA increases expression
mRNA 17374387
D014750 551 AVP
ADH
ARVP
AVP-NPII
AVRP
VP
arginine vasopressin Vincristine results in increased expression of AVP protein increases expression
protein 4356234
D014750 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 BAK1 protein affects the susceptibility to Vincristine affects response to substance
protein 22178383
D014750 581 BAX
BCL2L4
BCL2-associated X protein BAX protein affects the susceptibility to Vincristine affects response to substance
protein 22178383
D014750 581 BAX
BCL2L4
BCL2-associated X protein Vincristine results in decreased expression of BAX mRNA decreases expression
mRNA 16001973
D014750 581 BAX
BCL2L4
BCL2-associated X protein Vincristine results in increased cleavage of and results in increased expression of BAX protein increases cleavage
/ increases expression
protein 15131059
D014750 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 20162574
D014750 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Vincristine decreases expression
/ increases response to substance
protein 21258880
D014750 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 TYMP inhibits the reaction [Vincristine results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 15907805
D014750 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Vincristine results in increased phosphorylation of BCL2 protein increases phosphorylation
protein 15907805
D014750 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 BCL2L1 protein affects the susceptibility to Vincristine affects response to substance
protein 22178383
D014750 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset BRCA1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 675 BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCB
FANCD
FANCD1
GLM3
PNCA2
breast cancer 2, early onset BRCA2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 100170841 C17orf96
chromosome 17 open reading frame 96 C17ORF96 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 8618 CADPS
CADPS1
CAPS
CAPS1
Ca++-dependent secretion activator CADPS mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 84254 CAMKK1
CAMKKA
calcium/calmodulin-dependent protein kinase kinase 1, alpha (EC:2.7.11.17) CAMKK1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 21245421
D014750 57082 CASC5
AF15Q14
CT29
D40
KNL1
PPP1R55
Spc7
hKNL-1
hSpc105
cancer susceptibility candidate 5 CASC5 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 839 CASP6
MCH2
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) Vincristine results in increased expression of CASP6 mRNA increases expression
mRNA 16001973
D014750 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Vincristine results in increased expression of CASP8 mRNA increases expression
mRNA 16001973
D014750 847 CAT
catalase (EC:1.11.1.6) CAT protein affects the susceptibility to Vincristine affects response to substance
protein 11178967
D014750 890 CCNA2
CCN1
CCNA
cyclin A2 CCNA2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 891 CCNB1
CCNB
cyclin B1 CCNB1 protein affects the susceptibility to Vincristine affects response to substance
protein 22178383
D014750 960 CD44
CDW44
CSPG8
ECMR-III
HCELL
HUTCH-I
IN
LHR
MC56
MDU2
MDU3
MIC4
Pgp1
CD44 molecule (Indian blood group) CD44 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 157313 CDCA2
Repo-Man
cell division cycle associated 2 CDCA2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1020 CDK5
PSSALRE
cyclin-dependent kinase 5 (EC:2.7.11.22) CDK5 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1022 CDK7
CAK1
CDKN7
HCAK
MO15
STK1
p39MO15
cyclin-dependent kinase 7 (EC:2.7.11.23 2.7.11.22) CDK7 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A CDKN2A protein results in increased susceptibility to Vincristine increases response to substance
protein 16786135
D014750 1051 CEBPB
C/EBP-beta
CRP2
IL6DBP
LAP
LIP
NF-IL6
TCF5
CCAAT/enhancer binding protein (C/EBP), beta Vincristine results in increased expression of CEBPB mRNA increases expression
mRNA 16001973
D014750 11190 CEP250
C-NAP1
CEP2
CNAP1
centrosomal protein 250kDa CEP250 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 23563 CHST5
I-GlcNAc-6-ST
I-GlcNAc6ST
glcNAc6ST-3
gn6st-3
hIGn6ST
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 CHST5 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 57019 CIAPIN1
2810413N20Rik
Anamorsin
DRE2
PRO0915
cytokine induced apoptosis inhibitor 1 CIAPIN1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 18389626
D014750 23242 COBL
cordon-bleu WH2 repeat protein COBL mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1299 COL9A3
DJ885L7.4.1
EDM3
IDD
MED
collagen, type IX, alpha 3 COL9A3 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1396 CRIP1
CRHP
CRIP
CRP-1
CRP1
cysteine-rich protein 1 (intestinal) CRIP1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1 results in decreased susceptibility to Vincristine decreases response to substance
22000491
D014750 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 21245421
D014750 1559 CYP2C9
CPC9
CYP2C
CYP2C10
CYPIIC9
P450IIC9
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) CYP2C9 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 21245421
D014750 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein results in increased metabolism of Vincristine increases metabolic processing
protein 19346885
D014750 1577 CYP3A5
CP35
CYPIIIA5
P450PCN3
PCN3
cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) [CYP3A5 gene polymorphism results in increased activity of CYP3A5 protein] which results in increased metabolism of Vincristine increases activity
/ increases metabolic processing
gene / protein 21225912
D014750 1577 CYP3A5
CP35
CYPIIIA5
P450PCN3
PCN3
cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) CYP3A5 protein results in increased metabolism of Vincristine increases metabolic processing
protein 21225912
D014750 1582 CYP8B1
CP8B
CYP12
cytochrome P450, family 8, subfamily B, polypeptide 1 (EC:1.14.13.95) CYP8B1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1617 DAZ1
DAZ
SPGY
deleted in azoospermia 1 DAZ1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 57054 DAZ3
pDP1679
deleted in azoospermia 3 DAZ3 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 57135 DAZ4
pDP1680
pDP1681
deleted in azoospermia 4 DAZ4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 11056 DDX52
HUSSY19
ROK1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 (EC:3.6.4.13) DDX52 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 9046 DOK2
p56DOK
p56dok-2
docking protein 2, 56kDa DOK2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) DPYD gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 Vincristine results in increased expression of EGR1 mRNA increases expression
mRNA 12706485
D014750 79071 ELOVL6
FACE
FAE
LCE
ELOVL fatty acid elongase 6 (EC:2.3.1.199) ELOVL6 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2052 EPHX1
EPHX
EPOX
HYL1
MEH
epoxide hydrolase 1, microsomal (xenobiotic) (EC:3.3.2.9) EPHX1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) ERBB2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2068 ERCC2
COFS2
EM9
TTD
XPD
excision repair cross-complementing rodent repair deficiency, complementation group 2 (EC:3.6.4.12) ERCC2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 9156 EXO1
HEX1
hExoI
exonuclease 1 EXO1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) Vincristine affects the expression of F2 protein affects expression
protein 12542493
D014750 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Vincristine results in increased expression of F3 mRNA increases expression
mRNA 12542493
D014750 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) Vincristine results in increased expression of F3 protein increases expression
protein 12542493
D014750 84668 FAM126A
DRCTNNB1A
HCC
HLD5
HYCC1
family with sequence similarity 126, member A FAM126A mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 55215 FANCI
KIAA1794
Fanconi anemia, complementation group I FANCI mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Vincristine results in increased expression of FASLG protein increases expression
protein 11716366
D014750 9103 FCGR2C
CD32
CD32C
CDW32
FCG2
FCRIIC
IGFR2
Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene) FCGR2C mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2264 FGFR4
CD334
JTK2
TKF
fibroblast growth factor receptor 4 (EC:2.7.10.1) FGFR4 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 9896 FIG4
ALS11
CMT4J
KIAA0274
SAC3
YVS
dJ249I4.1
FIG4 homolog, SAC1 lipid phosphatase domain containing (S. cerevisiae) FIG4 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2528 FUT6
FCT3A
FT1A
Fuc-TVI
FucT-VI
fucosyltransferase 6 (alpha (1,3) fucosyltransferase) (EC:2.4.1.65) FUT6 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 26748 GAGE12I
AL4
CT4.7
GAGE-7B
GAGE7B
G antigen 12I GAGE12I mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2574 GAGE2C
CT4.2
GAGE-2
GAGE-2C
GAGE2
G antigen 2C GAGE2C mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2575 GAGE3 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2576 GAGE4
CT4.4
G antigen 4 GAGE4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2578 GAGE6
CT4.6
G antigen 6 GAGE6 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2579 GAGE7
AL4
CT4.7
GAGE-7
G antigen 7 GAGE7 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2729 GCLC
GCL
GCS
GLCL
GLCLC
glutamate-cysteine ligase, catalytic subunit (EC:6.3.2.2) [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Vincristine affects cotreatment
/ decreases response to substance
protein 10900222
D014750 2730 GCLM
GLCLR
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Vincristine affects cotreatment
/ decreases response to substance
protein 10900222
D014750 51608 GET4
C7orf20
CEE
TRC35
golgi to ER traffic protein 4 homolog (S. cerevisiae) GET4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2690 GHR
GHBP
growth hormone receptor GHR gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2735 GLI1
GLI
GLI family zinc finger 1 GLI1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2838 GPR15
BOB
G protein-coupled receptor 15 GPR15 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) GPX1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 gene polymorphism affects the susceptibility to Vincristine affects response to substance
gene 15713801
D014750 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 15044619
D014750 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) Sulfinpyrazone inhibits the reaction [GSTM1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 15044619
D014750 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] decreases response to substance
/ increases reaction
protein 10900222
D014750 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 10900222
D014750 2954 GSTZ1
GSTZ1-1
MAAI
MAI
glutathione S-transferase zeta 1 (EC:2.5.1.18 5.2.1.2) GSTZ1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2965 GTF2H1
BTF2
P62
TFB1
TFIIH
general transcription factor IIH, polypeptide 1, 62kDa GTF2H1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3044 HBBP1
hemoglobin, beta pseudogene 1 HBBP1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 113510 HELQ
HEL308
helicase, POLQ-like (EC:3.6.4.12) HELQ gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 9709 HERPUD1
HERP
Mif1
SUP
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 HERPUD1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3161 HMMR
CD168
IHABP
RHAMM
hyaluronan-mediated motility receptor (RHAMM) HMMR gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3265 HRAS
C-BAS/HAS
C-H-RAS
C-HA-RAS1
CTLO
H-RASIDX
HAMSV
HRAS1
K-RAS
N-RAS
RASH1
Harvey rat sarcoma viral oncogene homolog Vincristine results in increased expression of HRAS mRNA increases expression
mRNA 16001973
D014750 3316 HSPB2
HSP27
Hs.78846
LOH11CR1K
MKBP
heat shock 27kDa protein 2 HSPB2 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 17524270
D014750 3399 ID3
HEIR-1
bHLHb25
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein ID3 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
21245421
D014750 10561 IFI44
MTAP44
TLDC5
p44
interferon-induced protein 44 IFI44 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 3439 IFNA1
IFL
IFN
IFN-ALPHA
IFN-alphaD
IFNA13
IFNA@
interferon, alpha 1 IFNA1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) Vincristine promotes the reaction [NVP ADW742 inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 16740780
D014750 10643 IGF2BP3
CT98
IMP-3
IMP3
KOC1
VICKZ3
insulin-like growth factor 2 mRNA binding protein 3 IGF2BP3 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 3500 IGHG1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 3508 IGHMBP2
CATF1
HCSA
HMN6
SMARD1
SMUBP2
ZFAND7
immunoglobulin mu binding protein 2 (EC:3.6.4.13 3.6.4.12) IGHMBP2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Vincristine results in increased expression of IL6 mRNA increases expression
mRNA 16001973
D014750 9118 INA
NEF5
NF-66
TXBP-1
internexin neuronal intermediate filament protein, alpha INA affects the susceptibility to [Procarbazine co-treated with Lomustine co-treated with Vincristine] affects cotreatment
/ affects response to substance
21246521
D014750 9452 ITM2A
BRICD2A
E25A
integral membrane protein 2A ITM2A mRNA results in decreased susceptibility to Vincristine decreases response to substance
mRNA 20864405
D014750 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene JUN gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 3741 KCNA5
ATFB7
HCK1
HK2
HPCN1
KV1.5
PCN1
potassium voltage-gated channel, shaker-related subfamily, member 5 KCNA5 protein results in increased susceptibility to Vincristine increases response to substance
protein 17428690
D014750 9757 KMT2B
HRX2
MLL1B
MLL2
MLL4
TRX2
WBP7
lysine (K)-specific methyltransferase 2B (EC:2.1.1.43) KMT2B mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 3904 LAIR2
CD306
leukocyte-associated immunoglobulin-like receptor 2 LAIR2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 10859 LILRB1
CD85J
ILT-2
ILT2
LIR-1
LIR1
MIR-7
MIR7
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 LILRB1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 11006 LILRB4
CD85K
ILT-3
ILT3
LIR-5
LIR5
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 LILRB4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 4041 LRP5
BMND1
EVR1
EVR4
HBM
LR3
LRP7
OPPG
OPS
OPTA1
VBCH2
low density lipoprotein receptor-related protein 5 LRP5 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4049 LTA
LT
TNFB
TNFSF1
lymphotoxin alpha LTA gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4101 MAGEA2
CT1.2
MAGE2
MAGEA2A
melanoma antigen family A, 2 MAGEA2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 266740 MAGEA2B
MAGE2
MAGEA2
melanoma antigen family A, 2B MAGEA2B mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 23005 MAPKBP1
JNKBP-1
mitogen-activated protein kinase binding protein 1 MAPKBP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 22919 MAPRE1
EB1
microtubule-associated protein, RP/EB family, member 1 olesoxime inhibits the reaction [Vincristine results in decreased localization of MAPRE1 protein] decreases localization
/ decreases reaction
protein 20417191
D014750 22919 MAPRE1
EB1
microtubule-associated protein, RP/EB family, member 1 Vincristine results in decreased localization of MAPRE1 protein decreases localization
protein 20417191
D014750 22924 MAPRE3
EB3
EBF3
EBF3-S
RP3
microtubule-associated protein, RP/EB family, member 3 olesoxime inhibits the reaction [Vincristine results in decreased localization of MAPRE3 protein] decreases localization
/ decreases reaction
protein 20417191
D014750 22924 MAPRE3
EB3
EBF3
EBF3-S
RP3
microtubule-associated protein, RP/EB family, member 3 Vincristine affects the localization of MAPRE3 protein affects localization
protein 20417191
D014750 4153 MBL2
COLEC1
HSMBPC
MBL
MBL2D
MBP
MBP-C
MBP1
MBPD
mannose-binding lectin (protein C) 2, soluble MBL2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase Vincristine results in decreased expression of MDM2 mRNA decreases expression
mRNA 16001973
D014750 54842 MFSD6
MMR2
hMMR2
major facilitator superfamily domain containing 6 MFSD6 mRNA results in decreased susceptibility to Vincristine decreases response to substance
mRNA 20864405
D014750 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) MGMT affects the susceptibility to [Procarbazine co-treated with Vincristine co-treated with Nitrosourea Compounds] affects cotreatment
/ affects response to substance
16936459
D014750 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) MGMT gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) MGMT protein affects the susceptibility to [Procarbazine co-treated with Lomustine co-treated with Vincristine] affects cotreatment
/ affects response to substance
protein 16033832
D014750 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) [MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Vincristine affects cotreatment
/ decreases response to substance
protein 11792417
D014750 440823 MIAT
C22orf35
GOMAFU
LINC00066
NCRNA00066
RNCR2
myocardial infarction associated transcript (non-protein coding) MIAT mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 574456 MIR497
MIRN497
hsa-mir-497
microRNA 497 [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Vincristine decreases expression
/ increases response to substance
21258880
D014750 4288 MKI67
KIA
MIB-1
marker of proliferation Ki-67 MKI67 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 4548 MTR
HMAG
MS
cblG
5-methyltetrahydrofolate-homocysteine methyltransferase (EC:2.1.1.13) MTR gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4595 MUTYH
CYP2C
MYH
mutY homolog (EC:3.2.2.-) MUTYH gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog Vincristine results in decreased expression of MYC mRNA decreases expression
mRNA 16001973
D014750 4613 MYCN
MODED
MYCNOT
N-myc
NMYC
ODED
bHLHe37
v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Vincristine affects expression
/ affects response to substance
protein 10348353
D014750 4613 MYCN
MODED
MYCNOT
N-myc
NMYC
ODED
bHLHe37
v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog MYCN protein results in decreased susceptibility to Vincristine decreases response to substance
protein 10348353
D014750 53904 MYO3A
DFNB30
myosin IIIA (EC:2.7.11.1) MYO3A gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) NAT1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 4773 NFATC2
NFAT1
NFATP
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFATC2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 21245421
D014750 10577 NPC2
EDDM1
HE1
Niemann-Pick disease, type C2 NPC2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 NR1I2 protein promotes the reaction [Vincristine results in increased expression of ABCB1 protein] increases expression
/ increases reaction
protein 20041327
D014750 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Vincristine results in increased activity of NR1I2 protein increases activity
protein 20041327
D014750 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 [Vincristine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA increases activity
/ increases expression
protein 20041327
D014750 8829 NRP1
BDCA4
CD304
NP1
NRP
VEGF165R
neuropilin 1 NRP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 114880 OSBPL6
ORP6
oxysterol binding protein-like 6 OSBPL6 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 55644 OSGEP
GCPL1
KAE1
OSGEP1
PRSMG1
O-sialoglycoprotein endopeptidase (EC:3.4.24.57) OSGEP gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 8712 PAGE1
AL5
CT16.3
GAGE-9
GAGEB1
PAGE-1
P antigen family, member 1 (prostate associated) PAGE1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) PARP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 23178 PASK
PASKIN
STK37
PAS domain containing serine/threonine kinase (EC:2.7.11.1) PASK gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 301164 Vincristine results in increased expression of PCAF mRNA increases expression
mRNA 16001973
D014750 25894 PLEKHG4
ARHGEF44
PRTPHN1
SCA4
pleckstrin homology domain containing, family G (with RhoGef domain) member 4 PLEKHG4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 84898 PLXDC2
TEM7R
plexin domain containing 2 PLXDC2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5376 PMP22
CMT1A
CMT1E
DSS
GAS-3
HMSNIA
HNPP
Sp110
peripheral myelin protein 22 PMP22 gene mutant form results in increased susceptibility to Vincristine increases response to substance
gene 12427913
D014750 5423 POLB
polymerase (DNA directed), beta (EC:2.7.7.7) POLB gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5428 POLG
MDP1
MIRAS
MTDPS4A
MTDPS4B
PEO
POLG1
POLGA
SANDO
SCAE
polymerase (DNA directed), gamma (EC:2.7.7.7) POLG gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5445 PON2
paraoxonase 2 (EC:3.1.1.2 3.1.1.81) PON2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5467 PPARD
FAAR
NR1C2
NUC1
NUCI
NUCII
PPARB
peroxisome proliferator-activated receptor delta PPARD gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 84152 PPP1R1B
DARPP-32
DARPP32
protein phosphatase 1, regulatory (inhibitor) subunit 1B (EC:3.1.3.16) PPP1R1B protein results in increased susceptibility to Vincristine increases response to substance
protein 17470401
D014750 9055 PRC1
ASE1
protein regulator of cytokinesis 1 Vincristine results in increased expression of PRC1 mRNA increases expression
mRNA 17374387
D014750 5621 PRNP
ASCR
AltPrP
CD230
CJD
GSS
KURU
PRIP
PrP
PrP27-30
PrP33-35C
PrPc
p27-30
prion protein PRNP protein results in decreased susceptibility to Vincristine decreases response to substance
protein 15386405
D014750 57716 PRX
CMT4F
periaxin PRX gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5695 PSMB7
Z
proteasome (prosome, macropain) subunit, beta type, 7 (EC:3.4.25.1) PSMB7 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5740 PTGIS
CYP8
CYP8A1
PGIS
PTGI
prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) PTGIS gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5742 PTGS1
COX1
COX3
PCOX1
PES-1
PGG/HS
PGHS-1
PGHS1
PHS1
PTGHS
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) PTGS1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 2185 PTK2B
CADTK
CAKB
FADK2
FAK2
PKB
PTK
PYK2
RAFTK
protein tyrosine kinase 2 beta (EC:2.7.10.2) Vincristine results in increased phosphorylation of PTK2B protein increases phosphorylation
protein 11478917
D014750 5783 PTPN13
FAP-1
PNP1
PTP-BAS
PTP-BL
PTP1E
PTPL1
PTPLE
hPTP1E
protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) (EC:3.1.3.48) PTPN13 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 54870 QRICH1
glutamine-rich 1 Vincristine results in increased phosphorylation of QRICH1 protein increases phosphorylation
protein 17510977
D014750 84991 RBM17
SPF45
RNA binding motif protein 17 RBM17 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 16061639
D014750 159162 RBMY2FP
RNA binding motif protein, Y-linked, family 2, member F pseudogene RBMY2FP mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6001 RGS10
regulator of G-protein signaling 10 RGS10 protein results in increased susceptibility to Vincristine increases response to substance
protein 21044322
D014750 26575 RGS17
RGS-17
RGSZ2
hRGS17
regulator of G-protein signaling 17 RGS17 protein results in increased susceptibility to Vincristine increases response to substance
protein 21044322
D014750 6095 RORA
NR1F1
ROR1
ROR2
ROR3
RZR-ALPHA
RZRA
RAR-related orphan receptor A RORA mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6128 RPL6
L6
SHUJUN-2
TAXREB107
TXREB1
ribosomal protein L6 RPL6 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 15846068
D014750 6240 RRM1
R1
RIR1
RR1
ribonucleotide reductase M1 (EC:1.17.4.1) RRM1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 864 RUNX3
AML2
CBFA3
PEBP2aC
runt-related transcription factor 3 RUNX3 protein results in increased susceptibility to Vincristine increases response to substance
protein 15756676
D014750 949 SCARB1
CD36L1
CLA-1
CLA1
HDLQTL6
SR-BI
SRB1
scavenger receptor class B, member 1 SCARB1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6401 SELE
CD62E
ELAM
ELAM1
ESEL
LECAM2
selectin E SELE gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5055 SERPINB2
HsT1201
PAI
PAI-2
PAI2
PLANH2
serpin peptidase inhibitor, clade B (ovalbumin), member 2 SERPINB2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 SERPINE1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 21245421
D014750 6442 SGCA
50-DAG
A2
ADL
DAG2
DMDA2
LGMD2D
SCARMD1
adhalin
sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) SGCA mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 7979 SHFM1
DSS1
ECD
SEM1
SHFD1
SHSF1
Shfdg1
split hand/foot malformation (ectrodactyly) type 1 SHFM1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6492 SIM1
bHLHe14
single-minded family bHLH transcription factor 1 SIM1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6555 SLC10A2
ASBT
IBAT
ISBT
NTCP2
PBAM
solute carrier family 10 (sodium/bile acid cotransporter), member 2 SLC10A2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
21245421
D014750 9990 SLC12A6
ACCPN
KCC3
KCC3A
KCC3B
solute carrier family 12 (potassium/chloride transporter), member 6 SLC12A6 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6584 SLC22A5
CDSP
OCTN2
OCTN2VT
solute carrier family 22 (organic cation/carnitine transporter), member 5 SLC22A5 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 9154 SLC28A1
CNT1
HCNT1
solute carrier family 28 (concentrative nucleoside transporter), member 1 SLC28A1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6513 SLC2A1
DYT17
DYT18
DYT9
EIG12
GLUT
GLUT1
GLUT1DS
HTLVR
PED
solute carrier family 2 (facilitated glucose transporter), member 1 SLC2A1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 17520257
D014750 28232 SLCO3A1
OATP-D
OATP3A1
OATPD
SLC21A11
solute carrier organic anion transporter family, member 3A1 SLCO3A1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 10592 SMC2
CAP-E
CAPE
SMC-2
SMC2L1
structural maintenance of chromosomes 2 SMC2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6649 SOD3
EC-SOD
superoxide dismutase 3, extracellular (EC:1.15.1.1) SOD3 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6654 SOS1
GF1
GGF1
GINGF
HGF
NS4
son of sevenless homolog 1 (Drosophila) Vincristine results in increased expression of SOS1 mRNA increases expression
mRNA 16001973
D014750 54908 SPDL1
CCDC99
spindle apparatus coiled-coil protein 1 SPDL1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6716 SRD5A2
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) (EC:1.3.1.22) SRD5A2 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 6717 SRI
CP-22
CP22
SCN
V19
sorcin SRI protein results in decreased susceptibility to Vincristine decreases response to substance
protein 18423116
D014750 6756 SSX1
CT5.1
SSRC
synovial sarcoma, X breakpoint 1 SSX1 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6757 SSX2
CT5.2
CT5.2A
HD21
HOM-MEL-40
SSX
synovial sarcoma, X breakpoint 2 SSX2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6759 SSX4
CT5.4
synovial sarcoma, X breakpoint 4 SSX4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 548313 SSX4B
CT5.4
synovial sarcoma, X breakpoint 4B SSX4B mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 6772 STAT1
CANDF7
ISGF-3
STAT91
signal transducer and activator of transcription 1, 91kDa Vincristine results in increased expression of STAT1 mRNA increases expression
mRNA 16001973
D014750 6820 SULT2B1
HSST2
sulfotransferase family, cytosolic, 2B, member 1 (EC:2.8.2.2) SULT2B1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 55530 SVOP
SV2 related protein homolog (rat) SVOP mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 10732 TCFL5
CHA
E2BP-1
Figlb
bHLHe82
transcription factor-like 5 (basic helix-loop-helix) TCFL5 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 83660 TLN2
ILWEQ
talin 2 TLN2 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 50999 TMED5
CGI-100
p28
transmembrane emp24 protein transport domain containing 5 TMED5 mRNA results in decreased susceptibility to Vincristine decreases response to substance
mRNA 20864405
D014750 26022 TMEM98
transmembrane protein 98 TMEM98 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 944 TNFSF8
CD153
CD30L
CD30LG
tumor necrosis factor (ligand) superfamily, member 8 TNFSF8 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein results in increased susceptibility to Vincristine increases response to substance
protein 14704126
D014750 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Vincristine results in increased expression of TP53 protein increases expression
protein 12082016
15131059
D014750 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Vincristine results in increased glutathionylation of TP53 protein increases glutathionylation
protein 17555331
D014750 7167 TPI1
TIM
TPI
TPID
triosephosphate isomerase 1 (EC:5.3.1.1) TPI1 protein affects the susceptibility to Vincristine affects response to substance
protein 18309519
D014750 7173 TPO
MSA
TDH2A
TPX
thyroid peroxidase (EC:1.11.1.8) TPO mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 1200 TPP1
CLN2
LPIC
TPP-1
tripeptidyl peptidase I (EC:3.4.14.9) TPP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 7223 TRPC4
HTRP-4
HTRP4
TRP4
transient receptor potential cation channel, subfamily C, member 4 TRPC4 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 7251 TSG101
TSG10
VPS23
tumor susceptibility 101 TSG101 affects the susceptibility to Vincristine affects response to substance
15044860
D014750 706 TSPO
BPBS
BZRP
DBI
IBP
MBR
PBR
PBS
PKBS
PTBR
mDRC
pk18
translocator protein (18kDa) TSPO gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP inhibits the reaction [Vincristine results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
15907805
D014750 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) TYMS gene polymorphism affects the susceptibility to Vincristine affects response to substance
gene 15713801
D014750 7350 UCP1
SLC25A7
UCP
uncoupling protein 1 (mitochondrial, proton carrier) UCP1 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 7364 UGT2B7
UDPGT_2B9
UDPGT2B7
UDPGTH2
UGT2B9
UDP glucuronosyltransferase 2 family, polypeptide B7 (EC:2.4.1.17) UGT2B7 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 440279 UNC13C
unc-13 homolog C (C. elegans) UNC13C mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 7380 UPK3A
UP3A
UPIII
UPIIIA
UPK3
uroplakin 3A UPK3A mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 27340 UTP20
DRIM
UTP20, small subunit (SSU) processome component, homolog (yeast) UTP20 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor VDR gene polymorphism affects the susceptibility to Vincristine affects response to substance
gene 15713801
D014750 7481 WNT11
HWNT11
wingless-type MMTV integration site family, member 11 WNT11 mRNA results in increased susceptibility to Vincristine increases response to substance
mRNA 20864405
D014750 51646 YPEL5
yippee-like 5 (Drosophila) YPEL5 mRNA results in decreased susceptibility to Vincristine decreases response to substance
mRNA 20864405
D014750 169270 ZNF596
zinc finger protein 596 (EC:2.1.1.43) ZNF596 gene SNP results in increased susceptibility to Vincristine increases response to substance
gene 20864405
D014750 30834 ZNRD1
HTEX-6
Rpa12
TEX6
ZR14
hZR14
tctex-6
zinc ribbon domain containing 1 (EC:2.7.7.6) Verapamil inhibits the reaction [ZNRD1 protein results in decreased susceptibility to Vincristine] decreases reaction
/ decreases response to substance
protein 14726695
D014750 30834 ZNRD1
HTEX-6
Rpa12
TEX6
ZR14
hZR14
tctex-6
zinc ribbon domain containing 1 (EC:2.7.7.6) ZNRD1 protein results in decreased susceptibility to Vincristine decreases response to substance
protein 14726695

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (70)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#114500 Colorectal cancer; crc P84022
#614039 Cortical dysplasia, complex, with other brain malformations 1; cdcbm1 Q13509
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#237500 Dubin-johnson syndrome; djs Q92887
#128101 Dystonia 4, torsion, autosomal dominant; dyt4 P04350
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#600638 Fibrosis of extraocular muscles, congenital, 3a, with or without extraocular involvement; cfeom3a Q13509
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 P04626
#610140 Heart-hand syndrome, slovenian type P02545
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#143100 Huntington disease; hd P42858
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#237450 Hyperbilirubinemia, rotor type; hblrr Q9NPD5
Q9Y6L6
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#612438 Leukodystrophy, hypomyelinating, 6; hld6 P04350
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#611603 Lissencephaly 3; lis3 Q71U36
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#613112 Macrothrombocytopenia, autosomal dominant, tubb1-related Q9H4B7
#608516 Major depressive disorder; mdd P08172
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#610031 Polymicrogyria, symmetric or asymmetric; pmgysa Q9BVA1
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#604906 Schizophrenia 9; sczd9 P49798
#181500 Schizophrenia; sczd P49798
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#187950 Thrombocythemia 1; thcyt1 P40225
#190300 Tremor, hereditary essential, 1; etm1 P35462
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (70)

KEGG disease name UniProt
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
H00033 Adrenal carcinoma P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00227 Congenital amegakaryocytic thrombocytopenia (CAMT) P40225 (marker)
H00059 Huntington's disease (HD) P42858 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00838 Congenital fibrosis of the extraocular muscles (CFEOM) Q13509 (related)
H00268 Lissencephaly (LIS) Q71U36 (related)
H00208 Hyperbilirubinemia Q92887 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)

Diseases related to CTD interactions

265 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D015746 D014750 Abdominal Pain marker/mechanism
1319399
2857400
2859431
4163141
4294312
4352365
4552812
5660206
5813374
D020434 D014750 Abducens Nerve Diseases marker/mechanism
5813374
14970803
14970804
D058186 D014750 Acute Kidney Injury marker/mechanism
10454517
D000230 D014750 Adenocarcinoma marker/mechanism
therapeutic
675898
6340628
19825857
D000380 D014750 Agranulocytosis marker/mechanism
5813374
D000471 D014750 Alkalosis marker/mechanism
582354
D000505 D014750 Alopecia marker/mechanism
2862358
4294312
4348690
4352365
4551303
4559404
5067790
5254045
5660206
5813374
D000707 D014750 Anaphylaxis marker/mechanism
19018221
D000740 D014750 Anemia marker/mechanism
4551437
4552812
5813374
11846301
D000787 D014750 Angina Pectoris marker/mechanism
11724093
D000855 D014750 Anorexia marker/mechanism
4294312
5660206
17109847
D001037 D014750 Aphasia marker/mechanism
17356399
19936661
20363963
D001044 D014750 Aphonia marker/mechanism
3152952
D001146 D014750 Arrhythmia, Sinus marker/mechanism
2743273
D001201 D014750 Ascites marker/mechanism
6937637
D001254 D014750 Astrocytoma therapeutic
185991
939971
1312230
1432038
3171334
8186424
D001259 D014750 Ataxia marker/mechanism
657152
D001264 D014750 Athetosis marker/mechanism
657152
6316187
D001342 D014750 Autonomic Nervous System Diseases marker/mechanism
1329697
6385604
18754106
19936661
D053099 D014750 Azotemia marker/mechanism
4833837
D001763 D014750 Blepharoptosis marker/mechanism
4294312
5813374
15838404
16816519
D001766 D014750 Blindness marker/mechanism
1377296
1497023
6894223
19936661
D019575 D014750 Blindness, Cortical marker/mechanism
7459813
14515391
C536572 D014750 Bone Marrow failure syndromes marker/mechanism
182948
6964043
7074557
D019046 D014750 Bone Marrow Neoplasms therapeutic
2214347
D001927 D014750 Brain Diseases marker/mechanism
284172
1280054
3469437
4848646
5767018
6328836
6738836
6893362
7931469
19936661
D001930 D014750 Brain Injuries marker/mechanism
8413926
D001932 D014750 Brain Neoplasms therapeutic
185991
939971
1312230
6773738
7931469
8186424
9760072
15543016
D001943 D014750 Breast Neoplasms therapeutic
222433
3169098
4352365
D002051 D014750 Burkitt Lymphoma therapeutic
3965085
9186541
18782177
D002277 D014750 Carcinoma marker/mechanism
therapeutic
4352365
6964043
7844616
D002283 D014750 Carcinoma, Bronchogenic therapeutic
4559404
D018236 D014750 Carcinoma, Embryonal therapeutic
5027400
D002292 D014750 Carcinoma, Renal Cell therapeutic
16201981
D018288 D014750 Carcinoma, Small Cell therapeutic
165045
D002294 D014750 Carcinoma, Squamous Cell therapeutic
2482985
6189445
7074557
C535575 D014750 Carcinoma, squamous cell of head and neck therapeutic
19484992
D002295 D014750 Carcinoma, Transitional Cell marker/mechanism
8602639
D009202 D014750 Cardiomyopathies marker/mechanism
6940649
D002493 D014750 Central Nervous System Diseases marker/mechanism
1895154
D016543 D014750 Central Nervous System Neoplasms therapeutic
3359561
10963643
D002526 D014750 Cerebellar Diseases marker/mechanism
12401321
D002543 D014750 Cerebral Hemorrhage marker/mechanism
7931469
D002607 D014750 Charcot-Marie-Tooth Disease marker/mechanism
8600343
10519723
12679647
12756314
15382281
18837430
D002817 D014750 Chordoma therapeutic
4528471
D002819 D014750 Chorea marker/mechanism
6316187
D015179 D014750 Colorectal Neoplasms therapeutic
7960606
D003128 D014750 COMA marker/mechanism
4512319
4758426
6573227
D003221 D014750 Confusion marker/mechanism
7099798
19936661
D000013 D014750 Congenital Abnormalities therapeutic
20216233
D003248 D014750 Constipation marker/mechanism
1319399
2857400
2859431
2861395
3974093
4163141
4294312
4343318
4352365
5660206
5813374
10499201
12368705
19936661
20921909
D003316 D014750 Corneal Diseases marker/mechanism
4294312
D003328 D014750 Coronary Thrombosis marker/mechanism
11724093
D003389 D014750 Cranial Nerve Diseases marker/mechanism
182948
4290103
6385604
10390891
15838404
17710662
18754106
D003556 D014750 Cystitis marker/mechanism
4551437
8518042
D003680 D014750 Deglutition Disorders marker/mechanism
10942065
20167372
D003711 D014750 Demyelinating Diseases marker/mechanism
1497023
4290103
4314181
6303274
8600343
9452187
11587867
16698718
17279013
18766974
19935391
D058405 D014750 Desmoplastic Small Round Cell Tumor therapeutic
10555010
D003967 D014750 Diarrhea marker/mechanism
4294312
7534090
D004172 D014750 Diplopia marker/mechanism
5813374
D004195 D014750 Disease Models, Animal marker/mechanism
7659949
9619501
10321468
11335041
12710988
12865165
14637374
15713428
18932196
20830263
D006970 D014750 Disorders of Excessive Somnolence marker/mechanism
9571977
D056486 D014750 Drug-Induced Liver Injury marker/mechanism
6937637
D062787 D014750 Drug Overdose marker/mechanism
182948
5159844
D064420 D014750 Drug-Related Side Effects and Adverse Reactions marker/mechanism
therapeutic
1324459
4551437
4552812
4559404
7960606
7992551
16562778
18590705
D004401 D014750 Dysarthria marker/mechanism
10942065
20167372
20363963
D055154 D014750 Dysphonia marker/mechanism
16696885
D004487 D014750 Edema marker/mechanism
6937637
D004802 D014750 Eosinophilia marker/mechanism
4551437
D004806 D014750 Ependymoma therapeutic
3359561
16609949
D004830 D014750 Epilepsy, Tonic-Clonic marker/mechanism
6269235
D004890 D014750 Erythema marker/mechanism
9571977
D004938 D014750 Esophageal Neoplasms marker/mechanism
7844616
D005076 D014750 Exanthema marker/mechanism
9434832
D005155 D014750 Facial Nerve Diseases marker/mechanism
4294312
5813374
20167372
D005157 D014750 Facial Pain marker/mechanism
1319399
1407990
2857400
3974093
4163141
5813374
D005158 D014750 Facial Paralysis marker/mechanism
4309695
19770526
D005221 D014750 Fatigue marker/mechanism
6293321
D005242 D014750 Fecal Incontinence therapeutic
9375755
D005334 D014750 Fever marker/mechanism
179476
2636248
D005530 D014750 Foot Deformities marker/mechanism
4009878
8600343
D005683 D014750 Gagging marker/mechanism
16609949
D020234 D014750 Gait Ataxia marker/mechanism
4294312
D020233 D014750 Gait Disorders, Neurologic marker/mechanism
1319399
3152952
8859020
D005767 D014750 Gastrointestinal Diseases marker/mechanism
1939879
4294312
5254045
6089632
6150069
7960606
D018589 D014750 Gastroparesis marker/mechanism
19448908
D005910 D014750 Glioma therapeutic
1662522
12874004
19901110
D005911 D014750 Gliosis marker/mechanism
1497023
D020435 D014750 Glossopharyngeal Nerve Diseases marker/mechanism
1407990
D006212 D014750 Hallucinations marker/mechanism
7537641
17356399
D006311 D014750 Hearing Disorders marker/mechanism
17023056
D034381 D014750 Hearing Loss marker/mechanism
18669462
19415035
D006312 D014750 Hearing Loss, Bilateral marker/mechanism
7272895
11154039
12868558
D006319 D014750 Hearing Loss, Sensorineural marker/mechanism
2217048
7272895
D003639 D014750 Hearing Loss, Sudden marker/mechanism
12868558
D006331 D014750 Heart Diseases marker/mechanism
3169098
7466925
D018325 D014750 Hemangioblastoma therapeutic
3359561
D006402 D014750 Hematologic Diseases marker/mechanism
179476
6150069
D006408 D014750 Hematoma, Subdural marker/mechanism
7931469
D006417 D014750 Hematuria marker/mechanism
8518042
8602639
12748258
D006429 D014750 Hemiplegia marker/mechanism
20363963
D006461 D014750 Hemolysis marker/mechanism
11193445
D006463 D014750 Hemolytic-Uremic Syndrome marker/mechanism
therapeutic
1699855
2482985
6846975
11037870
D006504 D014750 Hepatic Veno-Occlusive Disease marker/mechanism
therapeutic
9191535
9251728
11194540
15981233
18839274
19701718
D006529 D014750 Hepatomegaly marker/mechanism
6287875
6937637
D006685 D014750 Hoarseness marker/mechanism
16609949
D006689 D014750 Hodgkin Disease therapeutic
934199
1329697
2531872
4007346
4348690
4352365
4916023
6089632
6092732
6459048
6896575
7313841
15147373
15922437
16135485
16794504
17290056
17606976
17701600
18293384
19770686
D006930 D014750 Hyperalgesia marker/mechanism
8783247
9452187
9619501
9698336
10321468
11983324
12749967
12759171
12809704
12865165
14637374
15082137
15235822
15713428
15875786
16098672
16472913
16530953
16545521
16556439
16632831
16676325
16982702
17572696
17989505
18234883
18492948
18652822
18766156
18799818
18930597
18938155
19276613
19300402
19336915
19448908
19571391
19815945
20081245
20431905
20830263
20846523
D006932 D014750 Hyperbilirubinemia marker/mechanism
6937637
D006947 D014750 Hyperkalemia marker/mechanism
4833837
D006973 D014750 Hypertension marker/mechanism
182948
6269235
7099798
9434832
12368705
D006987 D014750 Hypesthesia marker/mechanism
1329697
4294312
4343318
8859020
20379113
D006996 D014750 Hypocalcemia marker/mechanism
4833837
D020437 D014750 Hypoglossal Nerve Diseases marker/mechanism
20167372
D007008 D014750 Hypokalemia marker/mechanism
582354
D007010 D014750 Hyponatremia marker/mechanism
4356234
4974027
12051122
12368705
D007022 D014750 Hypotension marker/mechanism
182948
D007024 D014750 Hypotension, Orthostatic marker/mechanism
1148735
4393517
6396566
7407771
D007049 D014750 Iatrogenic Disease marker/mechanism
1280054
1895154
6573227
6893362
9856687
11587867
19935391
D045823 D014750 Ileus marker/mechanism
therapeutic
182948
2997407
3974093
4294312
4348690
4352365
5813374
6937637
8534764
D007177 D014750 Inappropriate ADH Syndrome marker/mechanism
182948
582354
1319399
1424076
2859431
4356234
6192229
6937637
7099798
9434832
9571977
10660739
12051122
12368705
D007418 D014750 Intestinal Pseudo-Obstruction marker/mechanism
9434832
D020767 D014750 Intracranial Thrombosis marker/mechanism
3111251
D007674 D014750 Kidney Diseases marker/mechanism
11305414
D007680 D014750 Kidney Neoplasms marker/mechanism
therapeutic
8602639
11194540
D007890 D014750 Leiomyosarcoma marker/mechanism
therapeutic
1421432
7844616
12748258
D053609 D014750 Lethargy marker/mechanism
6937637
D007938 D014750 Leukemia therapeutic
581272
630255
3875694
4163141
5286047
5660206
6149015
D007945 D014750 Leukemia, Lymphoid therapeutic
4348690
4512319
4833837
9415359
D015464 D014750 Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapeutic
16437142
D007951 D014750 Leukemia, Myeloid therapeutic
4348690
5767018
D015470 D014750 Leukemia, Myeloid, Acute therapeutic
4294312
4309695
4518764
4552812
D015477 D014750 Leukemia, Myelomonocytic, Chronic therapeutic
15981233
D007952 D014750 Leukemia, Plasma Cell therapeutic
4571885
D015473 D014750 Leukemia, Promyelocytic, Acute therapeutic
9001434
18766974
D015458 D014750 Leukemia, T-Cell therapeutic
18766974
D056784 D014750 Leukoencephalopathies marker/mechanism
therapeutic
10730638
14872029
15794179
20363963
D007970 D014750 Leukopenia marker/mechanism
2997407
4352365
4551437
4631913
5660206
7960606
D008107 D014750 Liver Diseases marker/mechanism
169340
D008175 D014750 Lung Neoplasms therapeutic
6189445
6964043
19825857
D008180 D014750 Lupus Erythematosus, Systemic therapeutic
1696192
D008223 D014750 Lymphoma therapeutic
630255
4512319
6396566
9571977
9681210
10963643
16546662
21986259
D016483 D014750 Lymphoma, AIDS-Related therapeutic
8697399
D016393 D014750 Lymphoma, B-Cell therapeutic
9375755
14515391
14872029
D016403 D014750 Lymphoma, Large B-Cell, Diffuse therapeutic
10578547
15307884
D008228 D014750 Lymphoma, Non-Hodgkin therapeutic
403727
581313
582354
657152
1243105
1329697
2217048
2861395
2872506
4301062
4348690
4352365
4393517
4551303
4916023
6429913
6683953
6722721
6894223
7155172
8384253
12172056
12427913
14970804
D016399 D014750 Lymphoma, T-Cell therapeutic
21226894
D008527 D014750 Medulloblastoma therapeutic
939971
3359561
7099798
19701718
19890797
D018328 D014750 Melanoma, Amelanotic therapeutic
15990972
D008580 D014750 Meningism marker/mechanism
284172
D008590 D014750 Meningoencephalitis marker/mechanism
6573227
D020422 D014750 Mononeuropathies marker/mechanism
169494
D016472 D014750 Motor Neuron Disease marker/mechanism
10390891
11241435
D019957 D014750 Motor Skills Disorders marker/mechanism
12401321
D009062 D014750 Mouth Neoplasms therapeutic
2482985
D009069 D014750 Movement Disorders marker/mechanism
1654424
3025992
8859020
D009101 D014750 Multiple Myeloma therapeutic
1445746
3838922
11154039
12791655
15528922
15609275
17050881
17097782
17355553
20864405
D009120 D014750 Muscle Cramp marker/mechanism
1659838
D009123 D014750 Muscle Hypotonia marker/mechanism
1939879
16609949
D018908 D014750 Muscle Weakness marker/mechanism
therapeutic
284172
1329697
2861395
2862358
3152952
3974093
4009878
4046919
4294312
4301062
4314181
4348690
4352365
5027400
5660206
5813374
8534764
8600343
8622042
10519723
10942065
12427913
17356399
19936661
D009133 D014750 Muscular Atrophy marker/mechanism
4290103
4294312
4314181
5813374
D009182 D014750 Mycosis Fungoides therapeutic
1850399
D009203 D014750 Myocardial Infarction marker/mechanism
693307
1243105
3960084
4007346
7313841
7572766
8781842
9415359
11724093
17284715
D017202 D014750 Myocardial Ischemia marker/mechanism
7809448
D020967 D014750 Myotonic Disorders marker/mechanism
934199
D009325 D014750 Nausea marker/mechanism
4294312
5660206
D009336 D014750 Necrosis marker/mechanism
6573227
10730638
D009362 D014750 Neoplasm Metastasis therapeutic
7960606
D018213 D014750 Neoplasms, Bone Tissue therapeutic
278643
D018302 D014750 Neoplasms, Neuroepithelial marker/mechanism
12325066
D009404 D014750 Nephrotic Syndrome therapeutic
9655358
D009410 D014750 Nerve Degeneration marker/mechanism
232962
1850399
4290103
4301062
4309019
4314181
5767018
6303274
7155172
7659949
9161096
9452187
10499201
11587867
12401321
14637374
16676325
16698718
16797537
19935391
D009422 D014750 Nervous System Diseases marker/mechanism
1324459
2195722
4551303
4974027
6089632
6192229
6277454
7534090
8146850
12552058
16437142
16562778
21245421
D009437 D014750 Neuralgia marker/mechanism
1324459
5660206
9619501
10321468
12710988
14637374
15713428
16472913
19936661
20846523
D019150 D014750 Neuroaxonal Dystrophies marker/mechanism
857581
D019954 D014750 Neurobehavioral Manifestations marker/mechanism
8413926
12401321
D009447 D014750 Neuroblastoma therapeutic
857581
4294312
18353067
D017599 D014750 Neuroectodermal Tumors therapeutic
12837982
D018241 D014750 Neuroectodermal Tumors, Primitive, Peripheral therapeutic
11956280
15823816
D009468 D014750 Neuromuscular Diseases marker/mechanism
278643
2997407
5254045
D020511 D014750 Neuromuscular Junction Diseases marker/mechanism
172049
D020258 D014750 Neurotoxicity Syndromes marker/mechanism
105807
182948
630255
1407990
1654424
2363100
2857400
2897788
3327022
3477471
3488849
4009878
6125275
6149015
6150069
6316187
6473007
6722721
6964043
7074557
8608515
9681224
10553948
11255732
11335041
11587867
11957264
15330181
17023056
17572696
18714154
18797198
19770526
19936661
20921909
21225912
D009503 D014750 Neutropenia marker/mechanism
4551303
7534090
9434832
11305414
11846301
C537844 D014750 Nonseminomatous germ cell tumor therapeutic
6208747
D015840 D014750 Oculomotor Nerve Diseases marker/mechanism
5813374
7511314
D000857 D014750 Olfaction Disorders marker/mechanism
16698718
D009837 D014750 Oligodendroglioma therapeutic
7931469
15015656
19901104
20842591
21246521
D009886 D014750 Ophthalmoplegia marker/mechanism
4294312
4314181
5813374
16816519
D009896 D014750 Optic Atrophy marker/mechanism
813350
1497023
6894223
7099798
D009901 D014750 Optic Nerve Diseases marker/mechanism
6512355
D020339 D014750 Optic Nerve Glioma therapeutic
16936459
D019226 D014750 Oral Ulcer marker/mechanism
6937637
D012516 D014750 Osteosarcoma therapeutic
310278
857581
6940649
22016816
D010051 D014750 Ovarian Neoplasms therapeutic
2859431
D010146 D014750 Pain marker/mechanism
1329697
1654424
2862358
3025992
3044635
4314181
4343318
4352365
5813374
8622042
12368705
17280922
17659836
D010190 D014750 Pancreatic Neoplasms therapeutic
9862568
D010243 D014750 Paralysis marker/mechanism
232962
539376
2531872
5813374
6937637
12116067
18176183
19935391
20216233
D010264 D014750 Paraplegia therapeutic
9375755
D010291 D014750 Paresis marker/mechanism
1329697
6316187
D010292 D014750 Paresthesia marker/mechanism
therapeutic
581313
1329697
1654424
1939879
2861395
2862358
2897788
2997407
3974093
4290103
4294312
4301062
4309019
4314181
4343318
4348690
4352365
4559404
4608355
5027400
5660206
5813374
7511314
8534764
10499201
10942065
12116067
12427913
17097782
20921909
D010302 D014750 Parkinson Disease, Secondary marker/mechanism
292457
D010523 D014750 Peripheral Nervous System Diseases marker/mechanism
172049
182948
1148735
1390351
1497023
1659838
1850399
1964745
2555214
2995593
3009012
4294312
4301062
4309019
4314181
4348690
4356234
6245189
6285279
6303274
6385604
6683953
6937637
7099798
7511314
7659949
8444217
8771166
8866126
9452187
9698336
10321468
10499201
10741703
10931481
11241435
11305414
11957264
12116067
12427913
12679647
12710988
12865165
14637374
15382281
15781834
16698718
16797537
17279013
17280922
17659836
17710662
18176183
18270703
18754106
18837430
19300402
19815945
19909482
19936661
20216233
20431905
20433602
20830263
20864405
21225912
D010842 D014750 Pica marker/mechanism
17109847
D011115 D014750 Polyneuropathies marker/mechanism
72789
182948
4290103
6092732
6773738
10217912
10363265
11030069
15838404
19770686
20532679
D011129 D014750 Polyradiculoneuropathy marker/mechanism
17594344
D015452 D014750 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapeutic
16816519
17710662
18176182
18191947
21064136
21225912
D054198 D014750 Precursor Cell Lymphoblastic Leukemia-Lymphoma therapeutic
200767
264958
284172
857581
1389541
2214347
2265121
2636248
2743273
2862358
2946315
3111251
3152952
3164090
3208869
3469437
3965085
4290103
4294312
4512319
5254045
5767018
6345018
6937637
7155172
7808368
8326402
8534764
8771166
9403207
9606397
9681224
9856687
10457124
10519723
10660739
11030069
11037870
11193445
11241435
11255732
11587867
11882230
12116067
12368705
12679647
14970803
15794179
15891567
16437142
16479196
16562778
16609949
16696885
17031686
17356399
17594344
17653912
18797198
18839274
19018221
19179723
19346885
19770526
19909482
20121554
20216233
20334462
20363963
20505534
21297632
D054218 D014750 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapeutic
12426685
20167372
20463610
D011471 D014750 Prostatic Neoplasms therapeutic
6340628
D011552 D014750 Pseudomonas Infections marker/mechanism
4631913
D016553 D014750 Purpura, Thrombocytopenic, Idiopathic therapeutic
1696192
D011782 D014750 Quadriplegia marker/mechanism
581313
3974093
4290103
10390891
12427913
D011928 D014750 Raynaud Disease marker/mechanism
6846998
7689922
15543016
D012008 D014750 Recurrence therapeutic
2214347
D012021 D014750 Reflex, Abnormal marker/mechanism
284172
581313
1319399
1329697
2861395
2897788
3152952
3974093
4290103
4294312
4301062
4309019
4309695
4314181
4343318
4348690
4352365
4356234
4552812
4559404
5660206
5813374
6245189
6265865
6285279
7511314
8600343
10499201
10942065
11030069
12427913
19936661
20921909
D051437 D014750 Renal Insufficiency therapeutic
12844235
D012131 D014750 Respiratory Insufficiency marker/mechanism
5027400
D012133 D014750 Respiratory Paralysis marker/mechanism
284172
D012135 D014750 Respiratory Sounds marker/mechanism
1405987
1939879
11882230
16609949
16696885
20505534
D012162 D014750 Retinal Degeneration marker/mechanism
813350
1497023
D012183 D014750 Retrograde Degeneration marker/mechanism
1497023
1964745
6245189
6265865
16930282
17267126
D012208 D014750 Rhabdomyosarcoma therapeutic
857581
9191535
11846301
18989167
D012512 D014750 Sarcoma, Ewing therapeutic
3690810
7155172
7603395
8600343
D012514 D014750 Sarcoma, Kaposi therapeutic
1377296
1497023
2981498
7534090
D013584 D014750 Sarcoma, Synovial therapeutic
7668875
D020426 D014750 Sciatic Neuropathy marker/mechanism
9161096
D012640 D014750 Seizures marker/mechanism
therapeutic
179476
182948
1319399
2859431
3164090
4512319
5660206
6429913
9434832
15794179
17031686
19936661
D012678 D014750 Sensation Disorders marker/mechanism
8384253
D018805 D014750 Sepsis marker/mechanism
4631913
D012871 D014750 Skin Diseases marker/mechanism
7534090
D012878 D014750 Skin Neoplasms therapeutic
20431905
D055752 D014750 Small Cell Lung Carcinoma therapeutic
177209
2858016
6293321
D020886 D014750 Somatosensory Disorders marker/mechanism
19936661
D013120 D014750 Spinal Cord Neoplasms therapeutic
3171334
D013125 D014750 Spinal Neoplasms therapeutic
4528471
D013163 D014750 Splenomegaly marker/mechanism
6937637
D013280 D014750 Stomatitis marker/mechanism
4294312
D013479 D014750 Superior Vena Cava Syndrome marker/mechanism
therapeutic
19018221
19770526
D015173 D014750 Supratentorial Neoplasms therapeutic
12837982
D013724 D014750 Teratoma therapeutic
2859431
D013736 D014750 Testicular Neoplasms therapeutic
5027400
D013921 D014750 Thrombocytopenia marker/mechanism
therapeutic
2981498
2997407
4352365
4551437
4552812
5813374
11305414
11846301
D013923 D014750 Thromboembolism marker/mechanism
7960606
D013927 D014750 Thrombosis marker/mechanism
2946315
3875694
D013964 D014750 Thyroid Neoplasms therapeutic
9571977
D014012 D014750 Tinnitus marker/mechanism
19415035
D014202 D014750 Tremor marker/mechanism
4518764
D020433 D014750 Trigeminal Nerve Diseases marker/mechanism
1407990
5813374
D014511 D014750 Uremia marker/mechanism
582354
D001745 D014750 Urinary Bladder Diseases marker/mechanism
5286047
15891567
D001749 D014750 Urinary Bladder Neoplasms marker/mechanism
therapeutic
2172608
4352365
7844616
8158853
12748258
D001750 D014750 Urinary Bladder, Neurogenic marker/mechanism
6876287
18176183
D014549 D014750 Urinary Incontinence marker/mechanism
17356399
D016055 D014750 Urinary Retention marker/mechanism
182948
5286047
19936661
D014555 D014750 Urination Disorders marker/mechanism
5813374
D002583 D014750 Uterine Cervical Neoplasms therapeutic
1699855
7074557
D020421 D014750 Vagus Nerve Diseases marker/mechanism
18932196
D020301 D014750 Vasospasm, Intracranial marker/mechanism
17356399
D014786 D014750 Vision Disorders marker/mechanism
4352365
D014826 D014750 Vocal Cord Paralysis marker/mechanism
1405987
1939879
10578547
11882230
16546662
16609949
16696885
19179723
20505534
D014832 D014750 Voice Disorders marker/mechanism
1654424
4352365
9681210
D014839 D014750 Vomiting marker/mechanism
5660206
9434832
D014855 D014750 Wallerian Degeneration marker/mechanism
539376
D014883 D014750 Water-Electrolyte Imbalance marker/mechanism
582354
D009396 D014750 Wilms Tumor therapeutic
169340
184343
2561915
6287875
7991279
9251728
9722902
15838404
19672975